On the upside
American Superconductor (Nasdaq: AMSC) reversed year ago losses to post a better than expected profit for the second quarter and lifted its guidance for the full year.
Third quarter earnings and revenue for Akamai Technologies (Nasdaq: AKAM) topped estimates and the company forecast fourth quarter income above expectations.
Bank of America-Merrill Lynch upgraded Genworth Financial (NYSE: GNW).
On the downside
The Food and Drug Administration denied approval of Transcept Pharmaceuticals' (Nasdaq: TSPT) sleep disorder treatment Intermezzo and requested more data due to safety concerns.
Cytokinetics (NYSE: CYTK) warned that the timeline to develop its heart failure drug omecamtiv mecarbil may take up to a year more than originally expected.
Third quarter earnings for Harmonic (NYSE: HLIT) plummeted to fall short of expectations.
In the broad market, advancing issues outpaced decliners by a margin of more than 4 to 1 on the NYSE and by nearly 7 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks soared 13 points to 579.